BPC-157

10mg Vial

2 July 2026Updated 29 August 2026

BPC-157

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for BPC-157.

Create free account Member login

Full range of benefits for BPC-157

Accelerates tendon and ligament healing in animal studies

Enhances muscle regeneration after injury (preclinical)

Protects and repairs GI mucosa; reduces ulcer severity in models

Promotes angiogenesis and blood vessel formation in wounds

Reduces inflammation and modulates cytokine responses in models

Improves intestinal barrier function in preclinical studies

May counteract NSAID-induced gastric and intestinal damage

Supports fibroblast migration and collagen deposition during repair

Shows neuroprotective and nerve-healing effects in animal models

Modulates nitric oxide signaling relevant to tissue repair

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 15 known interactions

Synergistic(3)Compatible(4)Monitor(4)Avoid(4)

Not recommended for concurrent use

Active malignancy or recent cancer history

Because BPC-157 may promote angiogenesis and tissue growth in preclinical studies, use in patients with active cancer or without oncological clearance should be avoided or undertaken only after specialist review.

Pregnancy and lactation

There are no adequate safety data in pregnant or breastfeeding humans, so BPC-157 should be used with caution or avoided in these populations until more evidence is available.

Concurrent potent pro-angiogenic therapies (e.g., recombinant VEGF, growth hormone/IGF-1)

Combining BPC-157 with other strong pro-angiogenic or growth-promoting agents could theoretically increase the risk of abnormal tissue proliferation and should be carefully evaluated by the treating clinician.

Unregulated formulations or non-pharmaceutical sources

Products obtained from unverified suppliers may have variable purity, potency, or sterility, and clinicians should evaluate source, quality, and dosing before recommending co-administration.

All interaction categories

Synergistic (3)

Platelet-rich plasma (PRP): Both PRP and BPC-157 promote tissue repair and angiogenesis in preclinical and early clinical contexts, so combined use may produce additive effects on soft-tissue and tendon healing, although high-quality human data are limited.
Mesenchymal stem cell therapy (MSC): BPC-157's reported pro-regenerative and anti-inflammatory actions could be complementary to MSC-based regenerative therapies, potentially enhancing engraftment and repair in musculoskeletal applications, based mainly on preclinical rationale.
Vitamin C (ascorbic acid): Vitamin C is a key cofactor for collagen synthesis and may support BPC-157's collagen-promoting effects, suggesting a potentially additive effect on wound and connective tissue repair.

Compatible (4)

Acetaminophen (paracetamol): Acetaminophen has no known pharmacological interaction with BPC-157 and can be used for symptomatic analgesia without expected adjustment.
Topical antibiotics (e.g., mupirocin): Topical antimicrobial agents used for wound management have no known interactions with BPC-157 and are compatible in local care protocols.
Systemic antibiotics (e.g., amoxicillin): Systemic antimicrobial therapy for infection control does not have reported interactions with BPC-157 and can be co-administered when indicated.
Local anaesthetics (e.g., lidocaine): Local anaesthetics used for procedural analgesia are not known to interact with BPC-157 and are considered compatible in clinical practice.

Monitor (4)

Anticoagulants (warfarin, DOACs): Because BPC-157 may influence healing and vascular biology, clinicians should monitor for bleeding complications and assess INR or clinical signs when combined with anticoagulants despite limited direct evidence.
Insulin and oral hypoglycaemic agents: Preclinical data suggest BPC-157 can affect gastrointestinal hormones and metabolic parameters, so blood glucose should be monitored and antidiabetic dosing adjusted as needed.
Immunosuppressants and biologic immunomodulators (e.g., anti-TNF agents): Given potential immunomodulatory and regenerative effects of BPC-157, therapeutic response and infection risk should be monitored when it is used concurrently with systemic immunosuppression.
Antihypertensive agents: BPC-157 may influence vascular tone and nitric oxide pathways in preclinical models, so blood pressure should be monitored when initiating or adjusting therapy with concurrent antihypertensives.

Avoid (4)

Active malignancy or recent cancer history: Because BPC-157 may promote angiogenesis and tissue growth in preclinical studies, use in patients with active cancer or without oncological clearance should be avoided or undertaken only after specialist review.
Pregnancy and lactation: There are no adequate safety data in pregnant or breastfeeding humans, so BPC-157 should be used with caution or avoided in these populations until more evidence is available.
Concurrent potent pro-angiogenic therapies (e.g., recombinant VEGF, growth hormone/IGF-1): Combining BPC-157 with other strong pro-angiogenic or growth-promoting agents could theoretically increase the risk of abnormal tissue proliferation and should be carefully evaluated by the treating clinician.
Unregulated formulations or non-pharmaceutical sources: Products obtained from unverified suppliers may have variable purity, potency, or sterility, and clinicians should evaluate source, quality, and dosing before recommending co-administration.